<DOC>
	<DOCNO>NCT02513199</DOCNO>
	<brief_summary>The purpose study develop good way treat liver cancer , know hepatocellular carcinoma HCC , still liver . Many treatment exist treat tumor liver small grow past certain size , local therapy surgery , Trans-Arterial Chemo Embolization ( TACE ) , Radiofrequency Ablation ( RFA ) effective . The purpose study test combination two know treatment - TACE Stereotactic Body Radiation Therapy ( SBRT ) - use together treat large difficult access liver tumor . Each treatment show work well limitation . The study combine treatment organize sequence monitor closely effective combination control tumor .</brief_summary>
	<brief_title>Combination Chemoembolization Stereotactic Body Radiation Therapy Unresectable Hepatocellular Carcinoma</brief_title>
	<detailed_description>Hepatocellular carcinoma ( HCC ) third ranked cause global cancer mortality . There increase incidence HCC United States last twenty year , largely due Hepatitis C epidemic increasingly relate well nonalcoholic fatty liver disease . This non-randomized pilot study assess objective response rate durability response combination Trans-Arterial Chemoembolization ( TACE ) immediate stereotactic body radiation therapy ( SBRT ) treatment unresectable hepatocellular carcinoma ( HCC ) . Eligible patient select base lesion great 3 cm would make ineligible local therapy TACE thermal ablation ( TA ) . Eligible , consent , register patient treat two session standard TACE ethiodol separate 4-week interval . After ensure adequate return baseline liver function , patient treat SBRT target lesion 30-45 Gy 5 fraction . Tumor response assess use mRECIST criterion well diffusion weight imaging ( DWI ) via Magnetic Resonance Imaging ( MRI ) surveillance . In addition , tolerability toxicity record via CTCAE v. 4.0 . The essential hypothesis study combination TACE SBRT &gt; 3 cm HCC produce high response rate durable control compare TACE alone .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>Participants must diagnose HCC either pathologically American Association Study Liver Diseases ( AASLD ) radiographic criterion ( Bruix Hepatology 2011 ) . The criterion specifies CT MRI intense arterial uptake follow `` washout '' contrast venousdelayed phase . Any atypical lesion must confirm biopsy . A single liver lesion tumor size ≥ 3 cm define maximal diameter axial dimension MRI . Included measurement enhance nonenhancing component lesion . Maximum tumor size 7 cm define maximal diameter axial dimension MRI . Age ≥ 18 year ChildPugh class A B7 without ascites ECOG score 0 No prior treatment current HCC . However , recurrent HCC resection may include . Ability understand willingness sign write informed consent document . Pregnancy assess via pregnancy test prior TACE repeat prior SBRT . Metastatic disease outside liver Vascular invasion evidence vessel occlusion radiographic evidence tumor thrombus . Contraindications MRI , include claustrophobia , metallic implant , pacemaker Tumor adequate radiation dosage safely deliver ( see dose constraint ) Prior therapeutic radiation therapy abdomen and/or low thorax define carina pelvic inlet . Inability provide inform consent base persistent lack understanding , inability find adequate translation , impair mental status mental retardation , drug induce , traumatic brain injury . Multiple liver tumor make patient BCLC Stage B Prior treatment , except surgical resection , lesion target protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Hepatocellular Carcinoma</keyword>
	<keyword>Trans-Arterial Chemoembolization</keyword>
	<keyword>Stereotactic Body Radiation Therapy</keyword>
	<keyword>HCC</keyword>
	<keyword>TACE</keyword>
	<keyword>SBRT</keyword>
</DOC>